SI-BONE

Corporate Overview

January 2020



Safe Harbor Statement

This presentation contains "forward-looking statements," which are statements related to future events, expectations, results, activities, events or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. Such statements are based on SI-BONE's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, especially the information contained in the Private Securities Litigation Reform Act of 1995. We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.



Transforming & Leading the Sacropelvic Space

Large Market ¹	Robust Clinical Data	Reimbursement Advantage	Market Leadership
\$2.7 billion annual U.S. opportunity	80+ published clinical studies/papers	282 million+ U.S. covered lives	Pioneering sacropelvic surgical solutions
279K potential U.S. procedures per year	2 randomized controlled trials	35 Exclusive iFuse payor policies	6,000+ iFuse U.S. procedures in 2019
~4% market penetration	5-year data	\$915 increased surgeon Medicare payment ²	60% iFuse estimated U.S. market share ³

1 Jensen M, Brant-Zawadzki M, Obuchowski N, et al. Magnetic Resonance Imaging of the Lumbar Spine in People Without Back Pain. N Engl J Med. 1994;331:69-116.; Bernard 1987, Schwarzer 1995,

SI-BONE

Maigne 1996, Irwin 2007, Sembrano 2009.; INSITE RCT data: 5 years in pain and 31% of patients screened were eligible for surgery.

2 As of January 1, 2020

3


3 Cantor Fitzgerald December 17, 2019 Initiation of Coverage document


Financial Profile

Strong Revenue Growth		Financial Leverage	
2019	2020		
\$67 - \$67.3M REVENUE ¹	\$80 - \$82M REVENUE ²	~90% GROSS MARGINS ³	1 tray case cost CAPITAL EFFICIENCY
21% GROWTH	19 – 22% GROWTH		



Major Joints Market





Sources: Jensen M, Brant-Zawadzki M, Obuchowski N, et al. Magnetic Resonance Imaging of the Lumbar Spine in People Without Bac Pain. N Engl J Med. 1994;331:69-116.; Bernard 1987, Schwarzer 1995, Maigne 1996, Irwin 2007, Sembrano 2009.; INSITE RCT data: years in pain and 31% of patients screened were eligible for surgery.

Pioneering sacropelvic surgical solutions

40,000+ Procedures

2,000+ Surgeons

282M+ Covered Lives

7 Note: As of December 31, 2019

SI-BONE

Diagnostic Algorithm Acceptance and Adoption

Results are **as good or better** than rules for other lumbar spine conditions



NASS NORTH AMERICAN SPINE SOCIETY MEDICARE (MACs)



PRIVATE PAYORS JAPANESE SACROILIAC JOINT RESEARCH SOCIETY




A Major Gap in Sacroiliac Joint Therapy


NON-SURGICAL MANAGEMENT		SURGERY		
MEDICATIONS, PHYSICAL THERAPY	THERAPEUTIC INJECTIONS	RADIO-FREQUENCY ABLATION	OPEN SI JOINT FUSION	MIS SI JOINT FUSION
	Medication			



Clinically Proven Minimally Invasive Solution

- Proven triangular design and procedure
- Porous, 3D-printed titanium implant
- Bony on-growth, in-growth, through-growth





Proprietary, Differentiated Technology


	SI Screws	iFuse
Rotation	 1X resistance 	 >6x resistance
Strength	 1X strength 	 3X strength¹
Safety	 Unknown 	 Very low complication rate
Revision	 Unknown 	 3.5% (4-year)
Clinical Evidence	 16 publications (no RCTs) 	 >80 publications
Surface	- Smooth	- Porous

SI-BONE

Notes: ECRI Price Guide Report, October 2016; Test Report. SI-BONE TS#300610 Revision A (vs. Rialto); Cher – Med Device Evid Res 2015; SI-BONE Corporate records, January 2018; <u>www.si-bone.com/results</u>; Spain & Holt – *Int J Spine Surg* 2017; Allowed only for the iFuse Implant[™], commercially available since 2009; <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5375000/</u> - 1- Based on iFuse

11

Comprehensive Sacropelvic Surgical Solution





Intellectual Property Overview

- 50 issued patents: U.S. (40), OUS (10)
- 22 pending patents: U.S. (17), OUS (5)


- iFuse patents cover until August 2024
- iFuse-3D patents cover until September 2035

SHAPE




Joint ... fused ... **a rectilinear bone fusion implant** ... across the joint

APPROACH



Lateral insertion path through the ilium and into the sacrum. A posterolateral insertion path angling through the SI joint.


3-D TECHNOLOGY



Fenestration is offset from both the distal end and the proximal end. One repeating internal portion comprising a plurality of apex struts.



Patient Experience






Robust Clinical Evidence

- >80 peer-reviewed published papers
- Long-term 5-year data
- Two level 1 randomized studies





5-Year Prospective Study, Including RCT



Published September 2019



Commercial Progress in 2019

Expand Sales	Influence	Increase Surgeon	Engage
Organization	Reimbursement	Activity	KOL's
100+ U.S. field personnel10 U.S. sales regions	 282M+ U.S. covered lives 27% increase in surgeon payment¹ 	539 active surgeons Focus on U.S. surgeon training	Bedrock procedure penetrating academic KOL centers 30+ academic centers trained



Investment in U.S. Salesforce


100+ FIELD PEOPLE

10 SALES REGIONS

- 107 FTEs in U.S. sales organization
 - 56 sales reps
 - **51** clinical support specialists
- **\$1.2M** average rep productivity



Growing U.S. Reimbursement



- 131 million covered by private payors
- All 7 Medicare MACS cover

- 35 U.S. exclusive policies
- 60+ million exclusive covered lives



Medicare Increased Surgeon Payment






Bedrock Technique Increasing Awareness of SI-Joint



- Bedrock technique as an adjunct to long fusion
- US Bedrock launched: June 2019
- "Open" or MIS technique
- Posterior: iFuse-3D implants parallel to S2AI screws
- Lateral: iFuse-3D implants plus S2AI screws
- iFuse biomechanical: >30% reduction in SIJ motion




Bedrock Case Studies



SI-BONE


Associate Professor Neurosurgery

Worldwide Revenue Growth



SI-BONE

U.S. Revenue Growth





2020 Outlook

- Expecting revenues of \$80 \$82 million, 19-22% growth
- Increasing U.S. field personnel and productivity
- Training activities to increase active surgeons
- Penetrating additional academic KOL centers with Bedrock
- Capitalizing on 27% increase in Medicare surgeon payment and additional payor coverage





Investment Highlights

>6,000 U.S. PROCEDURES IN 2019



279,000 U.S. POTENTIAL PATIENTS PER YEAR



SI-BONE

Disclosure

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.

The iFuse Implant System is also indicated for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion.

There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For more information on risks, please see http://www.si-bone.com/risks

One or more of the individuals named herein may be past or present SI-BONE employees, consultants, investors, clinical trial investigators, or grant recipients. Research described herein may have been supported in whole or in part by SI-BONE.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. iFuse-3D, iFuse Bone, iFuse Decorticator, iFuse Implant, iFuse Navigation, iFuse Bedrock and iFuse Neuromonitoring are trademarks of SI-BONE, Inc. © 2020 SI-BONE, Inc. All rights reserved.

